Summary Limited tumor penetrability of anti-cancer drugs is recognized as one of the major factors that lead to poor antitumor activity. SRJ09 (3,19-(2-bromobenzylidene) andrographolide) has been identified as a lead anti-cancer agent for colon cancer. Recently, this compound was shown by us to be a mutant K-Ras binder. In this present study, the penetrability of SRJ09 through the DLD-1 colon cancer multicell layer (MCL) was evaluated. The amount of SRJ09 that penetrated through the MCL was quantitated by utilizing high performance liquid chromatography (HPLC). Histopathological staining was used to visualize the morphology of MCL. A chemosensitivity assay was performed to assess the anticancer activity of SRJ09 in DLD-1 cells. SRJ09 was able to penetrate through DLD-1 MCL and is inversely proportional with the MCL thickness. The flow rates for SRJ09 through MCL were 0.90±0.20 μM/min/cm 2 and 0.56±0.06 μM/min/ cm 2 for days 1 and 5, respectively, which are better than doxorubicin. Histopathological examination revealed that the integrity of the DLD-1 MCL was retained and no visible damage was inflicted on the cell membrane, confirming the penetration of SRJ09 was by diffusion. Short term exposure (1 h) in DLD-1 cells demonstrated SRJ09 had IC 50 of 41 μM which was approximately 4-folds lower than andrographolide, the parent compound of SRJ09. In conclusion, SRJ09 successfully penetrated through DLD-1 MCL by diffusion and emerged as a potential candidate to be developed as a clinically viable anti-colon cancer drug.
Introduction
Chemotherapy is viewed as a systemic therapy as the drug is distributed through the circulatory system to eliminate cancer cells, especially those that have metastasized to different parts of the body [1] .
In order to destroy the tumor cells, especially those of clonogenic origin, also known as cancer stem cells, the drug needs to penetrate through the tumor within its pharmacokinetic lifespan [2] . The inner core of solid tumor normally contains areas which are transiently and sometimes chronically hypoxic, due to scarce supplies of blood vessels [3] . Hypoxic conditions and low extracellular pH within the tumor [4] proved to be the limiting factor that affects the efficacy of chemotherapy, as the drug has to penetrate through blood vessels and traverse through multiple layers of cells to reach the inner core of the tumor. The hypoxic environment in solid tumors is also normally associated with invasive and aggressive phenotype of cancers [5] .
Chemoresistance of cancer cells towards clinical anticancer agents have been identified as one of the major factors which contributes to the failure of chemotherapy, ultimately leading to refractory to treatment in cancer patients [6] . Most of the models proposing mechanism of resistance of cancer cells focused on mutation or over-expression of the key mediator proteins in the signaling cascade such as Notch, NF-κB, Akt and Raf [7] [8] [9] [10] . Over-expression of cell surface receptors such as epidermal growth factor receptor (EGFR), estrogen receptor (ER), platelet derived growth factor receptor (PDGFR) and insulin growth factor receptor (IGFR) have also been identified as possible mechanisms of resistance towards chemotherapy [11] [12] [13] [14] [15] .
The drug efflux pumps in cancers are also critical factors that are associated with diminished effect of chemotherapy [16] . A perfect example of such pumps would be Pglycoprotein (P-gp), which is widely studied and welldefined. P-gp acts by inhibiting the accumulation of anticancer drugs in cancer cells and its significance was substantiated by the findings that usage of P-gp inhibitors, verapamil successfully reversed the effect of P-gp on anti-cancer drugs in leukaemia cell lines [17] . However, the relationship between the P-gp and chemoresistance is not applicable on solid tumors, whereby many clinical reports [18] [19] [20] have indicated P-gp inhibitors failed to restore the chemoefficacy of anti-cancer drugs in tumor expressing P-gp [21] . Interestingly, the expression of P-gp is also greatly influenced by the hypoxic and acidic pH of the tumor microenvironment [22] . Furthermore, other drug efflux pumps such as multidrug-resistance associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) were also discovered as contributors towards chemoresistance [23, 24] .
Apart from the chemoresistance of cancer cells, the poor penetrability of anti-cancer drugs in solid tumors is also one of the factors that have contributed towards chemotherapy failure [4] . It has been well known that drug penetration barriers exist for some clinical anti-cancer agents that lead to diminished efficacy of chemotherapy [3, 4, 25, 26] . For instance, doxorubicin does not penetrate well through solid tumors in exerting its anti-tumor activity. This could be explained by the fact that doxorubicin exerts its anti-tumor activity by generating reactive oxygen species (ROS), which required the presence of oxygen. However, due to the hypoxic regions that are commonly found in solid tumors, it prevented the generation of ROS, greatly diminishing the anti-tumor activity of doxorubicin [27] . Furthermore, acidic conditions in the extracellular space of solid tumors decreases the anti-tumor activity of doxorubicin; low pH within tumor spheres interfere with the ability of doxorubicin to become ionized, which is required for its anti-cancer activity [28] .
3,19-(2-bromobenzylidene) andrographolide (SRJ09, Fig. 1 ) is a new anti-cancer drug lead. It was derived semisynthetically from andrographolide (AGP, Fig. 1 ), the main bioactive compound isolated from the traditional medicinal herb Andrographis paniculata [29] . SRJ09 was selected for further evaluation upon testing against the 60 cancer cell lines of National Cancer Institute (NCI) of USA; the compound displayed a pronounced difference in activity compared with AGP and other semisynthetic derivatives [29] . Of particular interest was its tumor type-selectivity for breast and colon cancers [29] . In our recent landmark study we showed that the compound disrupts mutant K-Ras oncoprotein activity by binding to it [30] . In this present investigation, the penetrability of SRJ09 through the DLD-1 colon cancer multi cell layer (MCL) was evaluated to further validate its potential as a new anti-cancer agent. In addition, chemosensitivity of DLD-1 to AGP and SRJ09 is presented.
Materials and methods

Cell line
DLD-1 colon cancer cell line was purchased from American Type Culture Collection (ATCC) (Manasass, Virginia, USA). Chemicals and reagents RPMI-1640, 0.5 % trypsin-EDTA (10X), penicillin (10,000 U/mL)-streptomycin (10 mg/mL), phosphate buffered saline (PBS), bovine serum albumins, 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) and Bouin's fluid were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). Dimethylsulfoxide (DMSO), methanol and glacial acetic acid were supplied by Fisher Scientific (Loughborough, Leicestershire, UK). AGP was isolated and purified from A. paniculata [31] , whereas the AGP derivatives were synthesized from AGP [31] .
Laboratory wares and consumables 
Instrumentations
Leitz rotary microtome was purchased from Leica UK (Milton Keynes, UK). Image analyzer used was obtained from Seescan (Cambridge, UK). High performance liquid chromatography (HPLC) system was supplied by Waters Corporation (Milford, Massachusetts, USA). ZORBAX Eclipse XDB-C18 column (4.6×150 mm, 3.5 μm) was obtained from Agilent Technologies (Santa Clara, USA). Filter holder was purchased from Alltech Associates Incorporated (Deerfield, Illinois, USA)
HPLC Method development
The HPLC system consisted of Waters 2695 Separation Module equipped with autosampler and Waters 2487 Dual UV Detector was utilized. The Empower 2 software was used for data acquisition. The separation was performed using C-18 column operated at ambient temperature and the compounds were detected at wavelength of 240 nm. For the assay, SRS07 was used as an internal standard throughout the HPLC analysis, as its structural and molecular weight were similar to SRJ09. Detailed method development, stability study and calibration curve are described in the Supplementary Methods Section.
Cell culture All tissue culture procedures were carried out in a sterile environment using a Class II biohazard cabinet and aseptic techniques were practiced. Good cell culture practice (GCCP) guidelines were followed during the whole process. DLD-1 colon cancer line were maintained in RPMI 1640 culture medium, supplemented with 10 % heatinactivated FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were grown in 25 cm 2 tissue culture flasks and incubated in a humidified atmosphere containing 5 % CO 2 at 37°C.
A total of 2.5×10 5 cells in 200 μL of RPMI-1640 culture medium were added to the top chamber of Transwell-COL plastic insert [2] . The top and bottom chambers were separated by a collagen-coated, microporous membrane (pore size 0.4 μm, diameter 6.5 mm, surface area 0.33 cm 2 ). Transwell vessels were incubated at 37°C for 3 h to allow cells to attach to the membrane before the addition of 2 mL of RPMI-1640 to the bottom chamber. Cells were incubated at 37°C in an atmosphere containing 5 % CO 2 for up to 5 days with daily changes of medium in both upper and lower chambers.
Drug penetration assay
Medium was removed from the top chamber of the transwell and replaced with 100 μL of medium (phenol red-free RPMI-1640 medium supplemented with 10 % fetal calf serum) containing SRJ09 at dose that represent peak plasma drug concentrations in vivo, which is 30.4 μM [36] . The transwell was then inserted into one well of a 24-well plate containing 600 μL of medium and incubated at 37°C. At 5 min thereafter, 500 μL of medium was taken from the bottom chamber and added to 1 mL of acetonitrile, mixed and stored at −20°C until required for analysis. The top chamber was replaced with fresh 100 μL of medium containing 30.4 μM of SRJ09 and placed in a new chamber containing 600 μL of medium. The procedures were repeated at every 5 min for a duration of 35 min. At all stages of the process, medium in the bottom chamber was agitated using a small magnetic stirrer. In the case of SRJ09, drug penetration was assessed on days 1 and 5 of the growth curve in order to determine the relationship between the thickness of the multi cell layer and the rate of penetration. All experiments were repeated independently on three occasions.
Sample extraction
The samples were thawed from −20°C and injected into HPLC for analysis. The sample extraction method is described in Supplementary Methods Section.
Data analysis
Drug concentrations in each sample were summated such that a graph of total drug penetration against time could be plotted. For example, drug concentrations at time point 1 were added to drug concentrations at time point 2 in order to obtain the total drug concentration in the lower chamber at time point 2.
Histopathological staining At various time points, inserts were removed, fixed in Bouin's fluid for 1 h and washed in 70 % ethanol and left in 70 % ethanol until processing. The membrane was detached from the plastic insert by using sharp scalpel blade and placed in automatic tissue processor for processing. After the process, the membrane was embedded in paraffin wax and sectioned (5 μm) using a Leitz rotary microtome (Leica UK, Milton Keynes, UK). Sections were stained with haematoxylin and eosin, and the average thickness of the multi cell layer determined by a Seescan image analyzer (Seescan, Cambridge, UK). Three separate transwells per time point were sectioned and the thickness of each multi cell layer was determined on five sections from each transwell (20 measurements per section). After 96 h of incubation, 20 μL of MTT solution (5 mg/mL) was added into each well of plates and incubated further for another 4 h. The supernatant was carefully removed and 150 μL of DMSO was added into each well to dissolve the formazan crystals formed in viable cells. The absorbance of purple formazan was read at 550 nm using a microplate reader and dose-response curves were constructed to determine the IC 50 values.
Statistical analysis
The data are represented as mean ± SD. Statistical Package for Social Sciences (SPSS) version 20 was utilized for data analysis. Statistical comparisons were made using one-way analysis of variance (ANOVA). A value of p<0.05 was considered to be significant.
Results
HPLC analysis
From the HPLC analysis, SRJ09 and SRJ07 had retention times of 4.9 and 6.0 min, respectively. The stability study of SRJ09 revealed that the compound was stable in acetonitrile, acidified acetonitrile and phenol red free RPMI (Supplementary data). The HPLC profiles of the compounds are described in Supplementary data.
Tumor penetration of SRJ09
From the drug penetration assay, SRJ09 successfully penetrated through the DLD-1 MCL with different thicknesses. The penetration of SRJ09 through the DLD-1 MCL was almost linear in fashion (Fig. 2) . The cumulative concentration of SRJ09 that managed to penetrate through the control well was approximately 15 μM whereas only approximately 6 μM successfully penetrated through the DLD-1 MCL for day 1, which is approximately 2.5 folds less when compared with without cells (Fig. 2a) . Similar trend was also observed for day 5 experiment, whereby the cumulative concentration of SRJ09 that managed to penetrate through the control well was approximately 14 μM whereas only approximately 4 μM successfully penetrated through the DLD-1 MCL, which is approximately 3.5 folds less when compared with without cells (Fig. 2b) .
Based on these results, it was found that the penetration of SRJ09 through the DLD-1 MCL was inversely proportionate to the thickness of DLD-1, whereby there was approximately 2 folds difference between the cumulative concentration of SRJ09 between day 1 and day 5 of the assay ( Table 1) .
The flow rate of SRJ09 was calculated based on the cumulative concentration of SRJ09 obtained for days 1 and 5. The flow rates of SRJ09 at day 1 and 5 were approximately 0.90 and 0.56 μM/min/cm 2 , respectively ( Table 1) . The difference between the flow rates was significant and therefore, it can be concluded that the thickness of the DLD-1 MCL affects the efficiency of SRJ09 penetration.
Histopathological section of DLD-1 MCL
The difference between the thicknesses of MCL at days 1 and 5 was slightly more than 2-fold (Table 1) . Upon histological examination of the samples, it was confirmed that MCL formed on day 1, as shown in Fig. 3a (ii) , whereby nuclei of the DLD-1 cells were located at different levels of the cells. Similarly, the thickness of the MCL at day 5 ( Fig. 3b (ii) ) was far greater than day 1, as indicated by the numerous nuclei at different levels of the cells. The integrity of the cell membrane of the DLD-1 MCL membrane remained intact, as indicated from the smooth surfaces of the MCL.
Chemosensitivity assay
The chemosensitivity of DLD-1 cells to AGP and SRJ09 was assessed to characterize the compounds' cytotoxicity profiles. Two different exposure times were chosen, which were 1 and 96 h (Fig. 4b) . The DLD-1 cells were exposed to various concentrations for 1 h as this was approximately the time needed for the completion of drug penetration assay. From the results obtained, both compounds had a very distinct cytotoxic activity (Table 2) . AGP, being the parent compound, had a weak cytotoxicity to DLD-1 cells, with an IC 50 value of approximately 151.4 μM. Whereas SRJ09 had an IC 50 value of approximately 40.7 μM, which was approximately 4-folds less than that of AGP (Table 2) .
Discussion
Reduced blood supply to tumors has been a major reason for poor outcome of chemotherapy. The cells that lie deep inside the tumor are normally responsible for the recurrence of cancer [4] . In order for the anti-cancer agents to exert their effects, they need to penetrate deep inside the tumor to eradicate tumor more effectively [4] . Therefore, the ability of the clinical anti-cancer agents to penetrate the tumor would ultimately improve the result of the chemotherapy. However, based on the preclinical studies, most of the clinical anti-cancer agents were found to have poor penetrability [3] . Hence, the quest to find a potential candidate with good anti-cancer activities and improved tumor penetrability is on-going and it proves to be a daunting task as not many successes have been reported.
In the drug penetration assay, SRJ09 successfully penetrated through DLD-1 MCL and its cumulative concentration was inversely proportional to the thickness of MCL. The cumulative concentration of SRJ09 could be correlated with the thickness of the MCL, whereby an increment of 2 folds in thickness will cause reduction of approximately 2 folds of cumulative concentration of SRJ09 (Table 1 ). This is due to the fact that an increase in the thickness of the MCL also means that the distance of SRJ09 needs to traverse through the MCL becomes longer, hence less SRJ09 could penetrate through the MCL at the end of the assay. Apart from that, the integrity of the cell membrane of the DLD-1 MCL membrane remained intact, as indicated from the smooth surfaces of the MCL cell membrane in the micrographs, effectively ruling out the possibility of the SRJ09 penetration was due to damage of the MCL cell membrane. From the results, SRJ09 successfully penetrated the DLD-1 MCL without inflicting any damage to the cell membrane integrity. Interestingly, SRJ09 has better penetrability than doxorubicin [32] , a clinical anti-cancer drug. This finding could be explained based on the lipophilicity and P-glycoprotein (P-gp) theory. To reach the target cells which are located deep within the tumor, anti-cancer drugs must diffuse through the extravascular compartment [33] . The relationship between lipophilicity and plasma membrane for small molecules have been well recognized and it is believed that lipophilic drugs or compounds were allowed to pass through the cells by transcellular transport, whereas the mode of transport of hydrophilic drugs or compounds through the cells is limited to paracellular transport [34] . SRJ09 is superior than doxorubicin in penetrating DLD-1 MCL very likely due to the fact that SRJ09 is more lipophilic than doxorubicin, as indicated by its higher log p value (5.5) compared with that of doxorubicin (−1.3) [35] .
In order to make an association between the penetrability and cytotoxicity of SRJ09, the concentration of compound that would be able to traverse the MCL for a specified time period should be considered. The IC 50 for 1 h was 40.7 μM and therefore longer exposure would undoubtedly produce IC 50 of less than this value, as seen with 96 h. If the cells are exposed to SRJ09 for 2 h, the concentration of compound that would be able to traverse the MCL is approximately 36 μM (0.9 μM/min/cm 2 ) X 120 min X 0.33 cm 2 ). This concentration could exert cytotoxicity to cancer cells that lie deep inside the tumor while penetrating through it within its pharmacokinetic life span. A previous pharmacokinetic study in mice supports this claim, whereby the availability of the compound, represented by area under the concentration versus time curve (AUC 0-2h ), was found to be 37 μM.h [36] . P-gp is an ATP-dependent drug transporter which is responsible for multidrug resistance (MDR) for many clinical anti-cancer drugs such as doxorubicin, vincristine, etoposide [37] . P-gp reduces the therapeutic effect of the drugs by actively pumping out doxorubicin within the cells to the extracellular space and hence hindering the drug from diffusing into the cells and exerting their effect [38] . P-gp was previously found to be intermediately over-expressed in DLD-1 cells [39] and hence this could possibly explain the reason behind the poor penetration of doxorubicin in DLD-1 MCL apart from being more hydrophilic.
The chemosensitivity assay of SRJ09 in DLD-1 cells was conducted in order to evaluate the anti-tumor activity of SRJ09 and AGP. Exposure of AGP on DLD-1 cells at the highest concentration (200 μM) for 1 h was able to kill 50 % of the cells at approximately 151.4 μM. However, SRJ09 was able to achieve IC 50 at much lower concentration (40.7 μM). The possible explanation for this observation is SRJ09 is more lipophilic than AGP [40] after the hydroxyl groups at position 3-C and 19-C of AGP were substituted with a 2-bromobenzylidene moiety. This may have increased the membrane lipid bilayer permeability of SRJ09 resulting in larger intracellular accumulation compared with AGP, therefore reducing the time of action of SRJ09 on DLD-1 cells compared with AGP.
The enhancement of the anti-tumor activity of SRJ09 can also be explained from the tumor biology perspective. Tumor biology has revealed that cancer cells are known to exhibit increased intrinsic oxidative stress. Compared with normal counterparts, most cancer cells have inherently increased amounts of reactive oxygen species (ROS), such as superoxide, hydrogen peroxide and hydroxyl radicals [41] . In the drug penetration model, a 3D MCL has been developed to mimic the actual tumor environment found in human body, which is hypoxic due to scarce blood supply. These conditions favorably create vast amount of ROS and this has been associated with cell proliferations, metastasis, angiogenesis and alteration of the cellular sensitivity to anti-cancer agents [42] . The benzene ring present in SRJ09 itself is an electron-withdrawing group, which readily undergo electrophic substitution reaction. This reaction is further enhanced by the introduction of bromo-group at the benzene ring, which is also an electron-withdrawing group that increases the electron density of benzene ring, all of which would increase the susceptibility of SRJ09 to undergo electrophilic substitution reaction and form pharmacologically active species [43] . This reaction could be catalyzed by the presence of vast amount of ROS, which is normally found in hypoxic region of tumors [44] , in this case the DLD-1 MCL.
In order to correlate the potential clinical relevance of the anticancer potential SRJ09, the characteristics of DLD-1 cell line are elaborated. This cell line is a colorectal adenocarcinoma isolated from male cancer patients and staged as Dukes' Type C according to the Duke System [45] . According to this staging system, the cancer cells had spread to at least one lymph node in the area near the bowel. In addition to the metastasizing property, a few tumor suppressor gene and oncogenes were also found to be mutated in DLD-1 cells. Among these were p53, myc, fos and Ras [46] . The coupling of these events made the DLD-1 cells relatively quite resistant towards chemotherapy. It is important to note that this tumor harbors mutant KRas [47] , an oncoprotein that has been suggested to be a target of SRJ09 [30] . Taking into account of its better tumor penetrability than doxorubicin and impressive in vitro anti-tumor activity, SRJ09 has great potential to be developed as an anti-cancer agent, particularly for the treatment of colon cancer.
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